Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public ...

BML Capital Management, an activist investor that owns 9.9% of Elevation’s shares, is urging the company to wind down ...

Losing the FDA’s senior negotiators would slow the renewal of the user fee programs “considerably,” according to policy and ...